CD4 and neoplasm: In summary, we observed elevated levels of THEMIS+ CD4+ T cells in tumor tissues from non-responsive patients, suggesting that this cell population may modulate the efficacy of anti-PD-1 treatment by regulating CD4+ T cell development.